Aurobindo Pharma injection drug Polymyxin B gets USFDA nod
New Delhi:Polymyxin B, injection an anti infective drug introduced by Aurobindo Pharma has received its final approval from US Food and Drug Administration for a launch in the second quarter of FY 16-17. It is a therapeutic equivalent to Eurohealth International Sarl's Polymyxin B for Injection USP. Polymyxin B for injection is used in treating urinary tract infections, meninges, among others.
The estimated market size for this Polymyxin B, injection is $7.6 million for the twelve months ending February 2016, according to IMS, the company has declared. Aurobindo now has a total of 252 Abbreviated New Drug Application (ANDA) approvals from the USFDA. Shares of the company were trading 0.25 per cent down at Rs 751.30 a piece on the BSE.
The estimated market size for this Polymyxin B, injection is $7.6 million for the twelve months ending February 2016, according to IMS, the company has declared. Aurobindo now has a total of 252 Abbreviated New Drug Application (ANDA) approvals from the USFDA. Shares of the company were trading 0.25 per cent down at Rs 751.30 a piece on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd